Apostolia M Tsimberidou

Apostolia M Tsimberidou

UNVERIFIED PROFILE

Are you Apostolia M Tsimberidou?   Register this Author

Register author
Apostolia M Tsimberidou

Apostolia M Tsimberidou

Publications by authors named "Apostolia M Tsimberidou"

Are you Apostolia M Tsimberidou?   Register this Author

100Publications

2970Reads

27Profile Views

A nonparametric Bayesian basket trial design.

Biom J 2019 Sep 28;61(5):1160-1174. Epub 2018 May 28.

Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77005, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bimj.201700162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261711PMC
September 2019

Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.

Cancer J 2019 Jul/Aug;25(4):296-299

Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000392DOI Listing
July 2019

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Arch Pathol Lab Med 2018 10 5;142(10):1242-1253. Epub 2018 Mar 5.

Jason D. Merker and Maximilian Diehn, Stanford University School of Medicine; Stanford, CA; Geoffrey R. Oxnard, Dana Farber Cancer Institute and Harvard Medical School; Neal Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Carolyn Compton, Arizona State University, Tempe, AZ; Patricia Hurley, Richard L. Schilsky, Thomas K. Oliver, and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Alexander J. Lazar and Apostolia M. Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; hristina M. Lockwood, University of Washington, Seattle, WA; Alex J. Rai, Columbia University Medical Center, New York, NY; Patricia Vasalos and Brooke L. Billman, College of American Pathologists, Northfield, IL; Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Nicholas C. Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-090
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0901-SADOI Listing
October 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Oncotarget 2018 Sep 4;9(69):33232-33243. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145698PMC
September 2018

Overview of precision oncology trials: challenges and opportunities.

Expert Rev Clin Pharmacol 2018 Aug 10;11(8):797-804. Epub 2018 Aug 10.

a Department of Investigational Cancer Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1504677DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330881PMC
August 2018

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Mol Cancer Ther 2018 07 13;17(7):1595-1601. Epub 2018 Apr 13.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310221PMC
July 2018

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

J Clin Oncol 2018 06 5;36(16):1631-1641. Epub 2018 Mar 5.

Jason D. Merker and Maximilian Diehn, Stanford University School of Medicine; Stanford, CA; Geoffrey R. Oxnard, Dana Farber Cancer Institute and Harvard Medical School; Neal Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Carolyn Compton, Arizona State University, Tempe, AZ; Patricia Hurley, Richard L. Schilsky, Thomas K. Oliver, and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Alexander J. Lazar and Apostolia M. Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; Christina M. Lockwood, University of Washington, Seattle, WA; Alex J. Rai, Columbia University Medical Center, New York, NY; Patricia Vasalos and Brooke L. Billman, College of American Pathologists, Northfield, IL; Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Nicholas C. Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8671DOI Listing
June 2018

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Mol Cancer Ther 2018 03 13;17(3):671-676. Epub 2017 Dec 13.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935561PMC
March 2018

Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.

Expert Opin Investig Drugs 2018 02 22;27(2):155-162. Epub 2018 Jan 22.

a MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics , The University of Texas , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2018.1430137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291242PMC
February 2018

Authors' Reply.

J Mol Diagn 2018 01;20(1):125-126

Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2017.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818630PMC
January 2018

Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

Expert Opin Biol Ther 2017 11 11;17(11):1463-1470. Epub 2017 Sep 11.

b Department of Investigational Cancer Therapeutics , MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1377178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166403PMC
November 2017

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

Int J Cancer 2017 Jan 17;140(1):208-215. Epub 2016 Oct 17.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30417DOI Listing
January 2017

Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?

Future Oncol 2015 ;11(14):1999-2002

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.82DOI Listing
May 2016

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 05 16;77(5):1097-102. Epub 2016 Apr 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3000-3DOI Listing
May 2016

Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.

Clin Genitourin Cancer 2016 Apr 11;14(2):e187-93. Epub 2015 Nov 11.

Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673150030
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2015.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783251PMC
April 2016

Health policy: Strategies to optimize expedited investigational new drug safety reports.

Nat Rev Clin Oncol 2016 Apr;13(4):207-8

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.42DOI Listing
April 2016

Precision medicine: lessons learned from the SHIVA trial.

Lancet Oncol 2015 Dec;16(16):e579-80

Center for Personalized Cancer Therapy, and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045150039
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00397-6DOI Listing
December 2015

Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.

Am Soc Clin Oncol Educ Book 2013 :118-25

From the Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden; American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.118DOI Listing
November 2015

Precision cancer medicine: the future is now, only better.

Am Soc Clin Oncol Educ Book 2014 :61-9

From the MD Anderson Cancer Center, Houston, TX; Institute Gustave-Roussy, Paris, France; American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/114000061-144
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2014.34.61DOI Listing
November 2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Invest New Drugs 2015 Aug 21;33(4):911-20. Epub 2015 May 21.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0251-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0251-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492845PMC
August 2015

A decision support framework for genomically informed investigational cancer therapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Apr 11.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy , the University of Texas MD Anderson Cancer Center, Houston, TX (FMB, AJ, VH, AMB, JZ, KRS, JM, GBM); Departments of Investigational Cancer Therapeutics (FMB, LB, SAPP, DSH, AMT), Surgical Oncology (FMB), Hematopathology (MR, KPP), Bioinformatics & Computational Biology (KC), GI Medical Oncology (SK), Melanoma Medical Oncology (MAD), Experimental Therapeutics (RB), Systems Biology (AKE, GBM), the University of Texas MD Anderson Cancer Center, Houston, TX; School of Biomedical Informatics, the University of Texas Health Science Center, Houston, TX (EVB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/7/djv098.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv098
Publisher Site
http://dx.doi.org/10.1093/jnci/djv098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651038PMC
July 2015

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Invest New Drugs 2015 Jun 31;33(3):621-31. Epub 2015 Mar 31.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, MD Anderson Cancer Center, Unit 455, P.O. Box 301402, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-015-0226
Web Search
http://link.springer.com/10.1007/s10637-015-0226-6
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0226-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482235PMC
June 2015

Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.

Curr Pharm Biotechnol 2014 ;15(5):475-85

Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.42, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389201015666140519123219DOI Listing
May 2015

Gene and cell therapy for pancreatic cancer.

Expert Opin Biol Ther 2015 Apr 13;15(4):505-16. Epub 2015 Jan 13.

National Center for Tumor Diseases and German Cancer Research Center, Department of Translational Oncology , Heidelberg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1001734DOI Listing
April 2015

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.

Cancer Chemother Pharmacol 2015 Apr 10;75(4):869-74. Epub 2015 Feb 10.

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2695-xDOI Listing
April 2015

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Invest New Drugs 2015 Feb 18;33(1):177-86. Epub 2014 Oct 18.

Sarah Cannon Research Institute at HealthONE, Presbyterian/St. Luke's Medical Center, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0173-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297242PMC
February 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Characteristics and survival of patients with advanced cancer and p53 mutations.

Oncotarget 2014 Jun;5(11):3871-9

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116527PMC
http://dx.doi.org/10.18632/oncotarget.2004DOI Listing
June 2014

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

Invest New Drugs 2014 Apr 12;32(2):279-86. Epub 2013 Jun 12.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9966-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730367PMC
April 2014

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.

J Natl Compr Canc Netw 2014 Feb;12(2):194-203

From the aDepartment of Investigational Cancer Therapeutics, and bDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0020DOI Listing
February 2014

Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis.

Biomicrofluidics 2013 16;7(1):11807. Epub 2013 Jan 16.

Department of Imaging Physics Research, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.4774304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562332PMC
January 2014

A pilot study of temsirolimus and body composition.

J Cachexia Sarcopenia Muscle 2013 Dec 27;4(4):259-65. Epub 2013 Jul 27.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13539-013-0113-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830004PMC
December 2013

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.

Invest New Drugs 2013 Dec 28;31(6):1505-13. Epub 2013 Aug 28.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0013-1DOI Listing
December 2013

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Mol Cancer Ther 2013 Dec 3;12(12):2857-63. Epub 2013 Oct 3.

Corresponding Author: Filip Janku, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, Texas 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0319-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158732PMC
December 2013

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases.

Cancer Chemother Pharmacol 2013 Dec 8;72(6):1265-71. Epub 2013 Oct 8.

Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, 1441 Moursund St., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2302-yDOI Listing
December 2013

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.

Clin Lymphoma Myeloma Leuk 2013 Oct 27;13(5):568-74. Epub 2013 Jun 27.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180513PMC
October 2013

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Mol Cancer Ther 2013 Oct 20;12(10):2167-75. Epub 2013 Aug 20.

Corresponding Author: Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138057PMC
October 2013

Anti-vascular endothelial growth factor therapy in the era of personalized medicine.

Cancer Chemother Pharmacol 2013 Jul 6;72(1):1-12. Epub 2013 Mar 6.

Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2124-yDOI Listing
July 2013

A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.

Cancer Chemother Pharmacol 2013 Apr 3;71(4):955-63. Epub 2013 Feb 3.

Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2088-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977741PMC
April 2013

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.

Cancer Chemother Pharmacol 2013 Feb 11;71(2):389-97. Epub 2012 Nov 11.

Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-2014-8DOI Listing
February 2013

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer Res 2013 Jan 12;73(1):276-84. Epub 2012 Oct 12.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862PMC
January 2013

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

Clin Colorectal Cancer 2012 Dec 25;11(4):297-303. Epub 2012 Apr 25.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2012.02.001DOI Listing
December 2012

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget 2012 Dec;3(12):1566-75

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495PMC
http://dx.doi.org/10.18632/oncotarget.716DOI Listing
December 2012

Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.

Hepatogastroenterology 2012 Jun;59(116):960-4

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5754/hge12189DOI Listing
June 2012

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.

Clin Cancer Res 2012 May 27;18(10):2922-9. Epub 2012 Mar 27.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176886PMC
May 2012